We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 76

The Myriad decision: what is the impact?
  • Bereskin & Parr LLP
  • Canada
  • June 20 2013

As we reported in our previous article, the Supreme Court of the United States issued its long awaited decision in the Myriad case on June 13, 2013


Patenting Polymorphs of Crystals Internationally
  • Bereskin & Parr LLP
  • Canada, European Union, Japan, USA
  • June 27 2016

Polymorphs are patentable subject matter in Canada and the U.S. Our prior article discussed some best practices to differentiate a new polymorph from


Supreme Court amends earlier decision: Viagra patent not void
  • Bereskin & Parr LLP
  • Canada
  • June 6 2013

In Teva Canada Ltd v Pfizer Canada Inc, the Supreme Court of Canada (the "SCC") held Pfizer's Canadian Patent No. 2,163,446 (the '446 Patent) to be


Looking into the Crystal Ball - Protecting Polymporphs to Lengthen the Drug Patent Life Cycle
  • Bereskin & Parr LLP
  • Canada, USA
  • June 7 2016

Innovative pharmaceutical companies are increasingly attempting to patent improved forms of their original drug compound. Crystalline forms of a drug


Evolution of the Common General Knowledge: Humanized Antibody Claims Upheld at the Canadian Patent Appeal Board
  • Bereskin & Parr LLP
  • Canada
  • August 26 2016

Applicants prevailed in the recent Commissioner’s Decision Re Chugai Seiyaku and Kabushiki Kaisha (CD 1398, hereinafter “Kaisha”) 1 from the Patent


Canadian Patent Term Extension - Bill is in the House
  • Bereskin & Parr LLP
  • Canada, European Union
  • November 2 2016

Canada and Europe finally signed off on the Comprehensive Economic and Trade Agreement ("CETA"). Its most significant aspect for the pharma industry


Canada’s Drug Linkage Regulations Finally Grow Up - Becoming a Full Action
  • Bereskin & Parr LLP
  • Canada
  • November 2 2016

Canada is taking steps to streamline drug patent owners' ability to enforce their patents. These steps should reduce the multiplicity of litigation


Gilead leave to appeal to Supreme Court of Canada dismissed re: FCA decision not to list patent on register due to lack of product specificity under PM(NOC) regulations
  • Bereskin & Parr LLP
  • Canada
  • March 21 2013

In Gilead Sciences Canada Inc. v. Canada (Minister of Health), 2012 FCA 254, the Federal Court of Appeal (FCA) dismissed Gilead's appeal of the


The Supreme Court of Canada grants leave to appeal in the Plavix case
  • Bereskin & Parr LLP
  • Canada
  • January 30 2014

The Supreme Court of Canada announced today that it has granted leave to appeal to Apotex Inc. from the Federal Court of Appeal (FCA) in the patent


Summary judgment for impeachment action of Viagra patent upheld by FCA
  • Bereskin & Parr LLP
  • Canada
  • January 24 2014

On January 22, 2014 the Federal Court of Appeal ("FCA") in Pfizer Ireland Pharmaceuticals v Apotex Inc, dismissed an appeal from the judgment of the